109 related articles for article (PubMed ID: 10656610)
1. Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients.
Mielicki WP; Tenderenda M; Rutkowski P; Chojnowski K
Cancer Lett; 1999 Nov; 146(1):61-6. PubMed ID: 10656610
[TBL] [Abstract][Full Text] [Related]
2. Correlation between increased granulocyte elastase release and activation of blood coagulation in patients with lung cancer.
Gabazza E; Taguchi O; Yamakami T; Machishi M; Ibata H; Suzuki S
Cancer; 1993 Oct; 72(7):2134-40. PubMed ID: 7690680
[TBL] [Abstract][Full Text] [Related]
3. Use of enzyme-linked immunosorbent assay to measure thrombin-antithrombin III complexes in horses with colic.
Topper MJ; Prasse KW
Am J Vet Res; 1996 Apr; 57(4):456-62. PubMed ID: 8712506
[TBL] [Abstract][Full Text] [Related]
4. [Coagulation and prothrombotic state parameters: clinical analysis in early pregnancy].
Chen LB; Meng LL; Chen H; Du BJ; Zhu LQ; Gao L; Zhang JP; Tan JP
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(27):2146-8. PubMed ID: 24284247
[TBL] [Abstract][Full Text] [Related]
5. Application of cancer procoagulant as an early detection tumor marker.
Kozwich DL; Kramer LC; Mielicki WP; Fotopoulos SS; Gordon SG
Cancer; 1994 Aug; 74(4):1367-76. PubMed ID: 8055461
[TBL] [Abstract][Full Text] [Related]
6. Cancer procoagulant in patients with adenocarcinomas.
Kaźmierczak M; Lewandowski K; Wojtukiewicz MZ; Turowiecka Z; Kołacz E; Lojko A; Skrzydlewska E; Zawilska K; Komarnicki M
Blood Coagul Fibrinolysis; 2005 Nov; 16(8):543-7. PubMed ID: 16269926
[TBL] [Abstract][Full Text] [Related]
7. Activation of the host response in human Plasmodium falciparum malaria: relation of parasitemia to tumor necrosis factor/cachectin, thrombin-antithrombin III, and protein C levels.
Hemmer CJ; Kern P; Holst FG; Radtke KP; Egbring R; Bierhaus A; Nawroth PP; Dietrich M
Am J Med; 1991 Jul; 91(1):37-44. PubMed ID: 1858827
[TBL] [Abstract][Full Text] [Related]
8. Assessment of coagulation disorders and cancer procoagulant activity in patients with myelodysplastic syndromes.
Chojnowski K; Treliński J; Wawrzyniak E; Sobolewska M; Mielicki W
Neoplasma; 2002; 49(3):155-8. PubMed ID: 12098000
[TBL] [Abstract][Full Text] [Related]
9. [D-dimer, thrombin-antithrombin III-complex (TAT) and prothrombin fragment 1+2 (PTF). Parameters for monitoring therapy with low molecular-weight heparin in coagulation disorders].
Hofmann M; Rest A; Hafner G; Tanner B; Brockerhoff P; Weilemann LS
Anaesthesist; 1997 Aug; 46(8):689-96. PubMed ID: 9382207
[TBL] [Abstract][Full Text] [Related]
10. [Thrombin markers in pregnant women: measurements of prothrombin fragments F 1+2 and thrombin-antithrombin III complexes (TAT) in the cord blood, the mother's blood and in amniotic fluid].
Uszyński W; Uszyński M; Zekanowska E
Ginekol Pol; 2004 Aug; 75(8):595-602. PubMed ID: 15517782
[TBL] [Abstract][Full Text] [Related]
11. Markers of coagulation activation after hepatic resection for cancer: evidence of sustained upregulation of coagulation.
Weinberg L; Scurrah N; Parker FC; Dauer R; Marshall J; McCall P; Story D; Smith C; McNicol L
Anaesth Intensive Care; 2011 Sep; 39(5):847-53. PubMed ID: 21970128
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of the high coagulation state of breast cancer tissue factor.
Mi XK; Liu QR; Zhu L; Sang MX; Guo LR; Shan BE
Eur Rev Med Pharmacol Sci; 2017 May; 21(9):2167-2171. PubMed ID: 28537667
[TBL] [Abstract][Full Text] [Related]
13. Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients.
Kemkes-Matthes B; Bleyl H
Ann Hematol; 1992 Jan; 64(1):35-9. PubMed ID: 1310878
[TBL] [Abstract][Full Text] [Related]
14. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum.
Rucińska M; Furman M; Skrzydlewski Z; Zaremba E
Acta Biochim Pol; 1997; 44(1):109-12. PubMed ID: 9241361
[TBL] [Abstract][Full Text] [Related]
15. Activation of blood coagulation in patients undergoing postoperative blood salvage and re-infusion of unwashed whole blood after total knee arthroplasty.
Biagini D; Filippucci E; Agnelli G; Pagliaricci S
Thromb Res; 2004; 113(3-4):211-5. PubMed ID: 15140585
[TBL] [Abstract][Full Text] [Related]
16. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease.
Woodward M; Lowe GD; Rumley A; Tunstall-Pedoe H; Philippou H; Lane DA; Morrison CE
Br J Haematol; 1997 Jun; 97(4):785-97. PubMed ID: 9217177
[TBL] [Abstract][Full Text] [Related]
18. Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.
Furmaniak-Kazmierczak E; Cooke TD; Manuel R; Scudamore A; Hoogendorn H; Giles AR; Nesheim M
J Clin Invest; 1994 Aug; 94(2):472-80. PubMed ID: 8040300
[TBL] [Abstract][Full Text] [Related]
19. Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis: determination of prothrombin fragment 1 + 2 and other markers.
Okamoto K; Takaki A; Takeda S; Katoh H; Ohsato K
Haemostasis; 1992; 22(1):17-24. PubMed ID: 1387863
[TBL] [Abstract][Full Text] [Related]
20. On-site prothrombin time, activated partial thromboplastin time, and platelet count. A comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery.
Despotis GJ; Santoro SA; Spitznagel E; Kater KM; Barnes P; Cox JL; Lappas DG
Anesthesiology; 1994 Feb; 80(2):338-51. PubMed ID: 8311316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
